Targeting sensory neurons to manage acute pain
Selective actin remodeling of sensory neurons for acute pain management
This study is exploring a new way to help people with sudden pain feel better using a special protein that targets the nerves responsible for pain, aiming to provide relief without the risks of addiction or side effects from regular pain medications.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neurocarrus, INC. NIH-funded |
| Lab location | 1 site (Monterey, United States) |
| Project ID | NIH-10603436 on NIH RePORTER |
What this research studies
This research investigates a novel approach to manage acute pain by selectively remodeling actin in sensory neurons. The method involves an engineered protein called N-001, which specifically targets sensory neurons to induce localized pain relief without affecting the central nervous system. By focusing on the cytoskeleton of these neurons, the treatment aims to reduce the risk of addiction and other side effects associated with traditional pain medications. The study builds on previous findings that demonstrated the feasibility of this approach in managing postoperative pain.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who experience acute pain, particularly those at risk for complications from traditional pain management therapies.
Not a fit: Patients with chronic pain conditions or those who do not respond to sensory neuron-targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, safer method for managing acute pain without the risk of substance use disorders.
How similar studies have performed: Previous research has shown promise in targeting sensory neurons for pain management, but this specific approach using N-001 is novel.
Where this research is happening
Monterey, United States
- Neurocarrus, INC. — Monterey, United States (Active)
Researchers
- Principal investigator: Blum, Paul — Neurocarrus, INC.
- Study coordinator: Blum, Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.